应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
XERS Xeris制药
休市中 08-23 16:00:00 EDT
2.88
+0.08
+2.86%
盘后
2.92
+0.04
+1.39%
18:09 EDT
最高
2.94
最低
2.83
成交量
154.87万
今开
2.83
昨收
2.80
日振幅
3.93%
总市值
4.29亿
流通市值
4.09亿
总股本
1.49亿
成交额
446.22万
换手率
1.09%
流通股本
1.42亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Xeris制药2024财年第二财季实现净利润-15.01百万美元,同比增加24.34%
自选股智能写手 · 08-18
Xeris制药2024财年第二财季实现净利润-15.01百万美元,同比增加24.34%
Xeris制药盘中异动 早盘股价大跌5.11%报2.41美元
自选股智能写手 · 08-14
Xeris制药盘中异动 早盘股价大跌5.11%报2.41美元
Xeris制药盘中异动 急速上涨5.11%报2.37美元
自选股智能写手 · 08-13
Xeris制药盘中异动 急速上涨5.11%报2.37美元
Xeris制药盘中异动 急速上涨5.38%
自选股智能写手 · 08-09
Xeris制药盘中异动 急速上涨5.38%
Xeris 生物制药控股公司公布截至 6 月的季度业绩 - 收益摘要
Reuters · 08-08
Xeris 生物制药控股公司公布截至 6 月的季度业绩 - 收益摘要
Xeris制药盘中异动 早盘股价大涨7.98%
自选股智能写手 · 08-08
Xeris制药盘中异动 早盘股价大涨7.98%
Xeris制药盘中异动 快速跳水5.09%
自选股智能写手 · 08-08
Xeris制药盘中异动 快速跳水5.09%
Xeris Biopharma Holdings Inc 预计每股亏损 11 美分 - 财报前瞻
Reuters · 08-06
Xeris Biopharma Holdings Inc 预计每股亏损 11 美分 - 财报前瞻
Xeris制药盘中异动 早盘股价大涨5.19%报2.54美元
自选股智能写手 · 07-25
Xeris制药盘中异动 早盘股价大涨5.19%报2.54美元
Xeris制药盘中异动 快速下挫5.11%报2.41美元
自选股智能写手 · 07-25
Xeris制药盘中异动 快速下挫5.11%报2.41美元
HC Wainwright & Co.:重申Xeris Biopharma Holdings(XERS.US)评级,由买入调整至买入评级, 目标价由6.
智通财经 · 05-31
HC Wainwright & Co.:重申Xeris Biopharma Holdings(XERS.US)评级,由买入调整至买入评级, 目标价由6.
Piper Sandler:重申Xeris Biopharma Holdings(XERS.US)评级,由增持调整至增持评级, 目标价由4.
智通财经 · 05-10
Piper Sandler:重申Xeris Biopharma Holdings(XERS.US)评级,由增持调整至增持评级, 目标价由4.
Xeris 生物制药控股公司公布截至一月的季度业绩 - 收益摘要
Reuters · 05-10
Xeris 生物制药控股公司公布截至一月的季度业绩 - 收益摘要
Xeris Biopharma Holdings Inc 预计每股亏损12美分 - 财报前瞻
Reuters · 05-08
Xeris Biopharma Holdings Inc 预计每股亏损12美分 - 财报前瞻
Xeris Biopharma Holdings(XERS.US)获奥本海默首次覆盖,给予优于大市评级, 目标价5.00美元。
智通财经 · 03-28
Xeris Biopharma Holdings(XERS.US)获奥本海默首次覆盖,给予优于大市评级, 目标价5.00美元。
Xeris 生物制药控股公司公布截至 12 月的季度业绩 - 收益摘要
Reuters · 03-06
Xeris 生物制药控股公司公布截至 12 月的季度业绩 - 收益摘要
Xeris Biopharma Holdings Inc 预计每股亏损10美分 - 财报前瞻
Reuters · 03-04
Xeris Biopharma Holdings Inc 预计每股亏损10美分 - 财报前瞻
加载更多
公司概况
公司名称:
Xeris制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Xeris Biopharma Holdings, Inc.于2005年根据特拉华州的法律成立。该公司致力于打造一家创新的、自我维持的、以增长为导向的生物制药公司,致力于通过开发一系列疗法中具有临床意义的产品并将其商业化来改善患者的生活。该公司具有独特的优势,通过三种商业产品和专有配方科学(XeriSol和XeriJect)来实现这一目标,从而建立合作伙伴关系并增强候选产品。
发行价格:
--
{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris制药","latestPrice":2.88,"timestamp":1724443200000,"preClose":2.8,"halted":0,"volume":1548688,"hourTrading":{"tag":"盘后","latestPrice":2.92,"preClose":2.88,"latestTime":"18:09 EDT","volume":19903,"amount":57328.1689,"timestamp":1724450953993},"delay":0,"floatShares":141879869,"shares":148998825,"eps":-0.421734,"marketStatus":"休市中","marketStatusCode":7,"change":0.08,"latestTime":"08-23 16:00:00 EDT","open":2.83,"high":2.94,"low":2.83,"amount":4462214.4465872,"amplitude":0.039286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.421734,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"listingDate":1529553600000,"adjPreClose":2.8,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":2.83,"preClose":2.8,"latestTime":"09:29 EDT","volume":1636,"amount":4656.410030399999,"timestamp":1724419799906},"postHourTrading":{"tag":"盘后","latestPrice":2.92,"preClose":2.88,"latestTime":"18:09 EDT","volume":19903,"amount":57328.1689,"timestamp":1724450953993},"volumeRatio":1.0448700850170423,"impliedVol":0.7585,"impliedVolPercentile":0.377},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2460398037","title":"Xeris制药2024财年第二财季实现净利润-15.01百万美元,同比增加24.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460398037","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460398037?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:02","pubTimestamp":1723910549,"startTime":"0","endTime":"0","summary":"8月18日,Xeris制药公布财报,公告显示公司2024财年第二财季净利润为-15.01百万美元,同比增加24.34%;其中营业收入为48.07百万美元,同比增加26.47%,每股基本收益为-0.10美元。从资产负债表来看,Xeris制药总负债3.51亿美元,其中短期债务5.31百万美元,资产负债比为0.95,流动比率为0.03。机构评级:截至2024年8月18日,当前有6家机构对Xeris制药目标价做出预测,其中目标均价为4.67美元,其中最低目标价为3.00美元,最高目标价为6.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180003599f3404cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180003599f3404cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS"],"gpt_icon":0},{"id":"2459174039","title":"Xeris制药盘中异动 早盘股价大跌5.11%报2.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459174039","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459174039?lang=zh_cn&edition=full","pubTime":"2024-08-14 21:43","pubTimestamp":1723643004,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日21时43分,Xeris制药股票出现波动,股价急速下挫5.11%。截至发稿,该股报2.41美元/股,成交量28.3741万股,换手率0.19%,振幅4.92%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。Xeris制药股票所在的生物技术行业中,整体跌幅为0.24%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081421432594200784&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081421432594200784&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2459900336","title":"Xeris制药盘中异动 急速上涨5.11%报2.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459900336","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459900336?lang=zh_cn&edition=full","pubTime":"2024-08-13 22:22","pubTimestamp":1723558979,"startTime":"0","endTime":"0","summary":"北京时间2024年08月13日22时22分,Xeris制药股票出现波动,股价大幅拉升5.11%。截至发稿,该股报2.37美元/股,成交量19.2216万股,换手率0.13%,振幅3.56%。Xeris制药股票所在的生物技术行业中,整体涨幅为1.20%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813222259aefe9ffa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813222259aefe9ffa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2458659591","title":"Xeris制药盘中异动 急速上涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458659591","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458659591?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:32","pubTimestamp":1723210379,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日21时32分,Xeris制药股票出现波动,股价急速拉升5.38%。截至发稿,该股报2.35美元/股,成交量3.4878万股,换手率0.02%,振幅4.48%。Xeris制药股票所在的生物技术行业中,整体涨幅为0.25%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213300aefe25bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213300aefe25bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2457312633","title":"Xeris 生物制药控股公司公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2457312633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457312633?lang=zh_cn&edition=full","pubTime":"2024-08-08 22:21","pubTimestamp":1723126903,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 报告,截至6月底的季度调整后每股亏损10美分,高于去年同期的每股-14美分。六位分析师对该季度的平均预期是每股亏损 11 美分。华尔街预期为每股-12美分至-9美分。* 营收同比增长 26.5%,达到 4807 万美元;分析师预期为 4581 万美元。* Xeris Biopharma Holdings Inc公布的本季度每股收益为亏损10美分。* 该公司当季亏损 1501 万美元。* Xeris Biopharma Holdings Inc本季度股价下跌了5.3%,今年迄今为止下跌了9.4%。华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xeris 生物制药控股公司公布截至 6 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2457311647","title":"Xeris制药盘中异动 早盘股价大涨7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457311647","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457311647?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:32","pubTimestamp":1723123929,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时32分,Xeris制药股票出现波动,股价快速上涨7.98%。截至发稿,该股报2.30美元/股,成交量12.0386万股,换手率0.08%,振幅7.04%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。Xeris制药股票所在的生物技术行业中,整体涨幅为1.16%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132099f1aa3f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132099f1aa3f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2457878471","title":"Xeris制药盘中异动 快速跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457878471","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457878471?lang=zh_cn&edition=full","pubTime":"2024-08-08 01:55","pubTimestamp":1723053321,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日01时55分,Xeris制药股票出现异动,股价急速下跌5.09%。截至发稿,该股报2.15美元/股,成交量115.694万股,换手率0.78%,振幅7.30%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。Xeris制药股票所在的生物技术行业中,整体跌幅为2.03%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080801552196824d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080801552196824d63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2457026437","title":"Xeris Biopharma Holdings Inc 预计每股亏损 11 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457026437","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457026437?lang=zh_cn&edition=full","pubTime":"2024-08-06 22:22","pubTimestamp":1722954147,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 将于8月8日公布截至2024年6月30日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,6位分析师的平均预期显示,这家总部位于芝加哥伊利诺伊州的公司的营收预计将从去年同期的3801万美元增长20.5%,达到4581.1万美元。* LSEG 分析师对 Xeris Biopharma Holdings Inc 的平均预期是每股亏损 11 美分。* 华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元,高于 2.23 美元的最新收盘价。8月6日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xeris Biopharma Holdings Inc 预计每股亏损 11 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2454280532","title":"Xeris制药盘中异动 早盘股价大涨5.19%报2.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454280532","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454280532?lang=zh_cn&edition=full","pubTime":"2024-07-25 23:13","pubTimestamp":1721920416,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日23时13分,Xeris制药股票出现波动,股价快速拉升5.19%。截至发稿,该股报2.54美元/股,成交量30.5608万股,换手率0.21%,振幅5.39%。Xeris制药股票所在的生物技术行业中,整体跌幅为0.38%。其相关个股中,Psyence Biomedical Ltd.、Salarius Pharmaceuticals, Inc.、Viking Therapeutics, Inc.涨幅较大,Salarius Pharmaceuticals, Inc.、Psyence Biomedical Ltd.、Exicure, Inc.较为活跃,换手率分别为2793.59%、487.72%、244.24%,振幅较大的相关个股有Psyence Biomedical Ltd.、Exicure, Inc.、Salarius Pharmaceuticals, Inc.,振幅分别为141.16%、132.26%、98.60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725231337aefb795a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725231337aefb795a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2454583100","title":"Xeris制药盘中异动 快速下挫5.11%报2.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454583100","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454583100?lang=zh_cn&edition=full","pubTime":"2024-07-25 02:44","pubTimestamp":1721846654,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日02时44分,Xeris制药股票出现异动,股价快速跳水5.11%。截至发稿,该股报2.41美元/股,成交量63.385万股,换手率0.43%,振幅4.92%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。Xeris制药股票所在的生物技术行业中,整体跌幅为0.44%。Xeris制药公司简介:Xeris Biopharma Holdings Inc 是一家生物制药公司,为内分泌学,神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725024414941fa356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725024414941fa356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2439433969","title":"HC Wainwright & Co.:重申Xeris Biopharma Holdings(XERS.US)评级,由买入调整至买入评级, 目标价由6.","url":"https://stock-news.laohu8.com/highlight/detail?id=2439433969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439433969?lang=zh_cn&edition=full","pubTime":"2024-05-31 18:28","pubTimestamp":1717151320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2434851155","title":"Piper Sandler:重申Xeris Biopharma Holdings(XERS.US)评级,由增持调整至增持评级, 目标价由4.","url":"https://stock-news.laohu8.com/highlight/detail?id=2434851155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434851155?lang=zh_cn&edition=full","pubTime":"2024-05-10 21:39","pubTimestamp":1715348372,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2434304913","title":"Xeris 生物制药控股公司公布截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2434304913","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434304913?lang=zh_cn&edition=full","pubTime":"2024-05-10 02:43","pubTimestamp":1715280215,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 报告,截至1月底的季度调整后每股亏损14美分,低于去年同期的每股收益-12美分。六位分析师对该季度的平均预期是每股亏损 12 美分。华尔街预期为每股-14美分至-11美分。* Xeris Biopharma Holdings Inc公布的本季度每股收益为亏损14美分。* 该公司当季亏损 1898 万美元。* Xeris Biopharma Holdings Inc 的股价本季度下跌了 16.3%,今年迄今为止下跌了 21.3%。* 医药同行的平均一致建议是 \"买入\"。华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2433247733","title":"Xeris Biopharma Holdings Inc 预计每股亏损12美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433247733","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433247733?lang=zh_cn&edition=full","pubTime":"2024-05-08 01:56","pubTimestamp":1715104612,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 将于5月9日公布截至2001年1月1日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,6位分析师的平均预期显示,这家总部位于芝加哥伊利诺伊州的公司的营收预计将从去年同期的3320万美元增长26.0%,达到4181.5万美元。* LSEG 分析师对 Xeris Biopharma Holdings Inc 的平均预期是每股亏损 12 美分。* 华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.75 美元,高于其上一次收盘价 1.90 美元。5月7日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2422166330","title":"Xeris Biopharma Holdings(XERS.US)获奥本海默首次覆盖,给予优于大市评级, 目标价5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2422166330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422166330?lang=zh_cn&edition=full","pubTime":"2024-03-28 18:51","pubTimestamp":1711623081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2417529213","title":"Xeris 生物制药控股公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2417529213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2417529213?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:42","pubTimestamp":1709736121,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 报告了截至12月底的季度调整后每股亏损10美分,与去年同期持平。华尔街预期为每股-13美分至-7美分。* 营收同比增长 33.9%,达到 4439 万美元;分析师预期为 4355 万美元。* Xeris Biopharma Holdings Inc公布的本季度每股收益为亏损10美分。* Xeris Biopharma Holdings Inc 的股价本季度上涨了 31.1%。3月6日 - 预测变化 * 在过去三个月中,分析师的平均盈利预测上升了约 3.9%。* 生物技术和医学研究同行的平均一致建议也是 \"买入\"。华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2416147731","title":"Xeris Biopharma Holdings Inc 预计每股亏损10美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2416147731","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416147731?lang=zh_cn&edition=full","pubTime":"2024-03-04 23:05","pubTimestamp":1709564729,"startTime":"0","endTime":"0","summary":" * Xeris Biopharma Holdings Inc 将于3月6日公布截至2023年12月31日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,4位分析师的平均预期显示,这家总部位于芝加哥伊利诺伊州的公司的营收预计将从去年同期的3314万美元增长31.4%,达到4355.2万美元。 * LSEG 分析师对 Xeris Biopharma Holdings Inc 的平均预期是每股亏损 10 美分。* 华尔街对 Xeris Biopharma Holdings Inc 的 12 个月目标价中位数为 4.50 美元,高于其上一次收盘价 3.18 美元。3月4日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.0706},{"period":"1month","weight":0.195},{"period":"3month","weight":0.4922},{"period":"6month","weight":-0.0432},{"period":"1year","weight":0.3333},{"period":"ytd","weight":0.2255}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xeris Biopharma Holdings, Inc.于2005年根据特拉华州的法律成立。该公司致力于打造一家创新的、自我维持的、以增长为导向的生物制药公司,致力于通过开发一系列疗法中具有临床意义的产品并将其商业化来改善患者的生活。该公司具有独特的优势,通过三种商业产品和专有配方科学(XeriSol和XeriJect)来实现这一目标,从而建立合作伙伴关系并增强候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.186811},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069518},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.024057},{"month":8,"riseRate":0.571429,"avgChangeRate":0.164842},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.094375},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059108},{"month":11,"riseRate":0.5,"avgChangeRate":0.006729},{"month":12,"riseRate":0.5,"avgChangeRate":0.047808}],"exchange":"NASDAQ","name":"Xeris制药","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xeris制药,XERS,Xeris制药股票,Xeris制药股票老虎,Xeris制药股票老虎国际,Xeris制药行情,Xeris制药股票行情,Xeris制药股价,Xeris制药股市,Xeris制药股票价格,Xeris制药股票交易,Xeris制药股票购买,Xeris制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}